Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PLAU | P00749 | 13/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.96 |
| ▸ | SLC9A5 | Q14940 | 4/20 | 0.96 |
| ▸ | TSHR | P16473 | 3/20 | 0.96 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL27563 | 0.98 | PLAU (1.00) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| Amiloride SCHEMBL29531132 | 0.98 | PLAU (1.00) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| Amiloride SCHEMBL136682 | 0.95 | PLAU (0.93) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| Amiloride SCHEMBL871514 | 0.93 | PLAU (0.90) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL2690754 | 0.89 | PLAU (0.83) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL13902826 | 0.84 | PLAU (0.75) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL14153334 | 0.84 | PLAU (0.75) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL15033062 | 0.84 | PLAU (0.75) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL10087514 | 0.83 | PLAU (0.73) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL13104159 | 0.81 | PLAU (0.71) | ALDH1A1KDM4EGLAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062309-A1 | Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor | DELGADO-ALMEIDA ANTONIO | 2009-03-05 | — | — | US | claimed |
| US-12473549-B2 | Splicing-dependent transcriptional gene silencing or activation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20230212577-A1 | SPLICING-DEPENDENT TRANSCRIPTIONAL GENE SILENCING OR ACTIVATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-06 | — | — | US | disclosed |
| US-11572560-B2 | Splicing-dependent transcriptional gene silencing or activation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220047608-A1 | Method of Treatment and Pharmaceutical Composition for Morning Hypertension | Dharma Laboratories LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3861119-A1 | SPLICING-DEPENDENT TRANSCRIPTIONAL GENE SILENCING OR ACTIVATION | Massachusetts Institute of Technology (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072125-A1 | SPLICING-DEPENDENT TRANSCRIPTIONAL GENE SILENCING OR ACTIVATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200109400-A1 | SPLICING-DEPENDENT TRANSCRIPTIONAL GENE SILENCING OR ACTIVATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3035931-B1 | COMPOSITION FOR REDUCING NERVOUS SYSTEM INJURY AND METHOD OF MAKING AND USE THEREOF | MOREHOUSE SCHOOL OF MEDICINE (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20090062309-A1 | Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor | DELGADO-ALMEIDA ANTONIO | 2009-03-05 | — | — | US | disclosed |
| WO-2004093814-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM CHANNEL BLOCKER | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093811-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM ION CHANNEL BLOCKER FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040220187-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2004-11-04 | — | — | US | disclosed |
| WO-2003086410-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR AND A DIURETIC AGENT | THE UNIVERSITY OF EDINBURGH (GB) | 2003-10-23 | — | — | WO | disclosed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | disclosed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
| US-5693462-A | MIXTURE OF A BICARBONATE, AN AMILORIDE-CONTAINING COMPOUND, WATER AND ADENOSINE, OPTIONAL OTHER CONSTITUENTS | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0797384-A1 | ORGAN TRANSPLANT SOLUTIONS AND METHOD FOR TRANSPLANTING AN ORGAN | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY doing business as Carolinas Medical Center (US) | 1997-10-01 | — | — | EP | disclosed |
| US-5554497-A | AMILORIDE | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1996018293-A1 | ORGAN TRANSPLANT SOLUTIONS AND METHOD FOR TRANSPLANTING AN ORGAN | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220187-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders | TRPV1, TRPV2, TRPA1 | SCNN1A 57/4885ALDH1A1 1721/4885KDM4E 3554/4885 |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | SCNN1A 3735/4885ALDH1A1 2724/4885KDM4E 4090/4885 |
| US-20090062309-A1 | Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor | PKD1, PKD2, ANO1 | SCNN1A 547/4885ALDH1A1 964/4885KDM4E 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.